These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
527 related articles for article (PubMed ID: 17290193)
21. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013 [TBL] [Abstract][Full Text] [Related]
22. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600 [TBL] [Abstract][Full Text] [Related]
23. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Chen L; Miller JW; Vavvas D; Kim IK Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258 [TBL] [Abstract][Full Text] [Related]
24. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Spaide RF; Sorenson J; Maranan L Ophthalmology; 2005 Feb; 112(2):301-4. PubMed ID: 15691567 [TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Abrams P Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187 [TBL] [Abstract][Full Text] [Related]
26. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Spaide RF; Sorenson J; Maranan L Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [TBL] [Abstract][Full Text] [Related]
28. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
29. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration. Datseris I; Kontadakis GA; Diamanti R; Datseris I; Pallikaris IG; Theodossiadis P; Tsilimbaris MK Semin Ophthalmol; 2015 Mar; 30(2):112-7. PubMed ID: 24117412 [TBL] [Abstract][Full Text] [Related]
30. Treatment of choroidal neovascularization using intravitreal bevacizumab. Pedersen R; Soliman W; Lund-Andersen H; Larsen M Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757 [TBL] [Abstract][Full Text] [Related]